About Agile Therapeutics
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: AGRX
- Previous Close: $2.24
- 50 Day Moving Average: $2.40
- 200 Day Moving Average: $5.90
- 52-Week Range: $1.82 - $8.65
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.85
- P/E Growth: 0.00
- Market Cap: $64.42M
- Outstanding Shares: 28,757,000
- Beta: 2.02
- Return on Equity: -57.50%
- Return on Assets: -40.30%
Companies Related to Agile Therapeutics:
- Debt-to-Equity Ratio: 0.26%
- Current Ratio: 6.55%
- Quick Ratio: 6.55%
What is Agile Therapeutics' stock symbol?
Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."
Where is Agile Therapeutics' stock going? Where will Agile Therapeutics' stock price be in 2017?
5 analysts have issued 12-month price objectives for Agile Therapeutics' stock. Their forecasts range from $7.00 to $15.00. On average, they anticipate Agile Therapeutics' stock price to reach $11.00 in the next year.
When will Agile Therapeutics announce their earnings?
Agile Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.
What are analysts saying about Agile Therapeutics stock?
Here are some recent quotes from research analysts about Agile Therapeutics stock:
Cantor Fitzgerald analysts commented, "Early this morning, AGRX announced the receipt of ~$3M in non-dilutive funding from converting unused Net Operating Loss (NOL) carryovers via the New Jersey Technology Business Tax Certificate Transfer Program. The addition of $3M, in our calculation, keeps their cash value through year- end at ~$50M, which should fund operations through 2017. This is the second time AGRX has used the program, converting ~$6M in Dec." (12/1/2016)
According to Zacks Investment Research, "Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey. " (5/11/2016)
Who owns Agile Therapeutics stock?
Agile Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include ProQuest Associates IV LLC (17.60%), Vivo Capital LLC (5.26%), Franklin Resources Inc. (4.72%), Perceptive Advisors LLC (2.30%), Deerfield Management Co. (1.38%) and Royce & Associates LP (1.12%). Company insiders that own Agile Therapeutics stock include Alfred Altomari and Jay Moorin.
Who sold Agile Therapeutics stock? Who is selling Agile Therapeutics stock?
Agile Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC, J. Goldman & Co LP and Franklin Resources Inc..
Who bought Agile Therapeutics stock? Who is buying Agile Therapeutics stock?
Agile Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Deerfield Management Co., Highland Capital Management LP, Renaissance Technologies LLC, First Light Asset Management LLC and State Street Corp. Company insiders that have bought Agile Therapeutics stock in the last two years include Alfred Altomari and Jay Moorin.
How do I buy Agile Therapeutics stock?
Shares of Agile Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Agile Therapeutics stock cost?
One share of Agile Therapeutics stock can currently be purchased for approximately $2.24.